PrEP Use High but Wanes after Three Months Among Young African Women

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use. 

UW HIV Prevention Research Highlighted at International Conference

UW Department of Global Health researchers presented new HIV prevention findings at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid. HIVR4P is the only global scientific conference focused exclusively on the challenging and fast-growing field of biomedical HIV prevention research.  The conference supports global cross-fertilization among research on HIV vaccines, microbicides, PrEP, treatment as prevention, and other biomedical prevention approaches.

The Lancet: Profile of Jared Baeten, Aiming to See Off HIV

By Tony Kirby

"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”. 

NewsBeat: Antiretrovirals Pose Low Risk to Nursing Mothers, Babies

Study involves researchers with UW International Clinical Research Center

By Bobbi Nodell

Researchers have found that breastfeeding mothers taking the antiretroviral drugs tenofovir and emtricitabine have a low risk of side effects. The study, published in PLOS, was conducted by colleagues at the UW International Clinical Research Center and partners in Kenya, Uganda and Johns Hopkins University.

Family Practice News: Oral HIV PrEP Also Protects Against Herpes

By Bruce Jancin

DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.

“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.

UW Awarded DREAMS Innovation Challenge to Bring PrEP to Adolescents in Kenya

The University of Washington is one of 56 DREAMS Innovation Challenge winners* announced on Monday by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Janssen Pharmaceutica NV (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson; and ViiV Healthcare.